¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°, ¾Ï À¯Çüº°, ÁÖ¿ä Áö¿ªº° - ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø(- 2035³â)
Cancer Biomarkers Market by Type of Biomarker, Type of Cancer and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035
»óǰÄÚµå : 1682715
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 309 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,943,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 10,126,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 15,335,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 26,042,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2035³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÇ¾î ÇöÀç 286¾ï ´Þ·¯¿¡¼­ 2035³â±îÁö 467¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦ µî ÀϺΠ¸é¿ªÄ¡·áÁ¦ÀÇ ÀÓ»óÀû ¼º°øÀº ¿©·¯ °íÇü¾Ï¿¡¼­ ÀÌ¹Ì ÀÔÁõµÈ ¹Ù ÀÖ½À´Ï´Ù. ±×·¯³ª ƯÁ¤ ¾ÏÁ¾¿¡ °É¸° ´Ù¾çÇÑ È¯ÀÚµéÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â Ä¡·á¹ý Æò°¡¿¡ ´ëÇÑ ¹ÌÃæÁ· ¼ö¿ä´Â ¿©ÀüÈ÷ Á¸ÀçÇÕ´Ï´Ù. °°Àº ¾Ï(°°Àº º´±â)À» ¾Î°í Àִ ȯÀÚ¶ó ÇÒÁö¶óµµ ºÐÀÚ ÇÁ·ÎÆÄÀÏÀÌ ´Ù¸£°í, ±ÇÀåµÇ´Â ¾à¹°/Ä¡·á¹ý¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ´Ù¸¦ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ȯÀÚ¿¡°Ô ´õ ³ªÀº °á°ú¸¦ ¾ò±â À§Çؼ­´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾Ï ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿´Â °³º° Á¾¾çÀÇ ºÐÀÚÀû Ư¡¿¡ ´ëÇÑ ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇϰí, ÀÓ»óÀǰ¡ °¢ ȯÀÚÀÇ °íÀ¯ÇÑ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

¾Ï ¹ÙÀÌ¿À¸¶Ä¿´Â ½ºÅ©¸®´×, ¾Ï ºÐ·ù, À§Çèµµ Æò°¡, Á¾¾ç ºÎÇÏ ÆÇ´Ü, Ä¡·á ¸ÂÃãÈ­ ¹× ¸ð´ÏÅ͸µ, ¿¹ÈÄ ¿¹Ãø µî ¾Ï Ä¡·áÀÇ ´Ù¾çÇÑ Ãø¸é¿¡¼­ Ȱ¿ëµÉ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖÀ¸¸ç, ±× ¹Ì·¡´Â ¸Å¿ì À¯¸ÁÇÕ´Ï´Ù. ¶ÇÇÑ, À¯Àüü, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐ, ¸¶ÀÌÅ©·Î RNomic ÇÁ·ÎÆÄÀϸµ, ºñ±³À¯ÀüüÇÏÀ̺긮µ¥À̼Ç(CGH), ´ÜÀÏ¿°±â´ÙÇü¼º(SNP) ºÐ¼®, ÇÏÀ̽º·çDz½ºÅ©¸®´×(HTS), Â÷¼¼´ë¿°±â¼­¿­ºÐ¼®(NGS) µîÀÇ ±â¼úÀÌ ¹ßÀüÇϸ鼭 »õ·Î¿î Á¾¾ç ½Ã±×´Ïó¸¦ ¹ß°ßÇÒ ¼ö ÀÖ´Â ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. »õ·Î¿î Á¾¾ç ½Ã±×´Ïó¸¦ ¹ß°ßÇÒ ¼ö ÀÖ´Â ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °­·ÂÇÑ ´Ü¹éÁúüÇÐ ¹× À¯Àüü ±â¼úÀÇ ÃâÇö°ú ¼øÈ¯Á¾¾ç¼¼Æ÷(CTC), ¾Ï Áٱ⼼Æ÷ ƯÀÌÀû ¸¶Ä¿ ¹× ¼¼Æ÷°¡ ¾ø´Â ¼øÈ¯Á¾¾ç DNA(ctDNA) ºÐ¼®ÀÌ °áÇÕÇÏ¿© ¾ÏÀÇ Á¶±â ¹ß°ß, º´ÀÇ ÁøÇà ¸ð´ÏÅ͸µ ¹× ÀûÀýÇÑ Ä¡·á¹ý ¼±ÅÃÀ» À§ÇÑ º¸´Ù ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÇ ºü¸¥ ¼Óµµ¿Í °³ÀÎÈ­ Á¢±Ù¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ´çºÐ°£ ÁÖ¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇöÀç ½ÃÀå¿¡´Â ¾à 100°³ÀÇ »õ·Î¿î ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ¼Ö·ç¼ÇÀÌ Ãâ½ÃµÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¼Ö·ç¼ÇÀÇ ´ëºÎºÐÀº ¾Ï ¹ÙÀÌ¿À¸¶Ä¿¸¦ Æò°¡Çϱâ À§ÇØ Â÷¼¼´ë ½ÃÄö½ÌÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù.

Cancer Biomarkers Market-IMG1

ÀÌ ¾÷°èÀÇ ÀÌÇØ°ü°èÀÚµéÀº ´Ù¾çÇÑ ¿ëµµÀÇ ½Å±Ô ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖÀ¸¸ç, ÀÌµé ¼Ö·ç¼ÇÀÇ 70% ÀÌ»óÀÌ MSI/MMR Æò°¡¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ¼Ö·ç¼Ç Á¦°ø¾÷üÀÇ ÇöÀç ½ÃÀå ȯ°æÀº ´ÜÆíÈ­µÇ¾î ÀÖÀ¸¸ç, ½Å±Ô ÁøÃâ±â¾÷°ú ±âÁ¸ ±â¾÷ ¸ðµÎ Á¸ÀçÇÕ´Ï´Ù. ÇöÀç »õ·Î¿î ¾Ï ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¿¬±¸Çϱâ À§ÇØ ´Ù¾çÇÑ Áö¿ª¿¡¼­ ¾à 685°ÇÀÇ ÀÓ»ó½ÃÇè(75,000¸í ÀÌ»óÀÇ È¯ÀÚ µî·Ï)ÀÌ ÁøÇà ÁßÀÔ´Ï´Ù. ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß¿¡¼­´Â ´Ù¾çÇÑ ¿¬±¸Àڵ鿡 ÀÇÇØ 470Æí ÀÌ»óÀÇ ³í¹®ÀÌ ¹ßÇ¥µÇ´Â µî ¿¬±¸°¡ ´«¿¡ ¶ç°Ô ÁøÀüµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÐ¾ß¿¡ ´ëÇÑ ¿©·¯ ¾÷°è ¹× ÇаèÀÇ °ü½ÉÀÌ ³ô¾ÆÁ³À½À» º¸¿©ÁÝ´Ï´Ù. ±â¼ú Çõ½Å°ú Á¦ÈÞ È°µ¿ Áõ°¡ ¼Óµµ¿¡ ÈûÀÔ¾î ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ´çºÐ°£ ²ÙÁØÈ÷ ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2035³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2035³â±îÁö ºÏ¹Ì°¡ ½ÃÀåÀÇ ´ëºÎºÐ(45% ÀÌ»ó)À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Cancer Biomarkers Market-IMG2

¼¼°èÀÇ ¾Ï ¹ÙÀÌ¿À¸¶Ä¿(Cancer Biomarker) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°/¾Ï À¯Çüº°/ÁÖ¿ä Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °æÁ¦ ¹× ±âŸ ÇÁ·ÎÁ§Æ® ƯÀ¯ÀÇ °í·Á»çÇ×

Á¦4Àå ÁÖ¿ä ¿ä¾à

Á¦5Àå ¼­·Ð

Á¦6Àå ½ÃÀå ±¸µµ

Á¦7Àå Á¦Ç° °æÀï·Â ºÐ¼®

Á¦8Àå ±â¾÷ °³¿ä

Á¦9Àå ¹ÙÀÌ¿À¸¶Ä¿¿¡ ±Ù°ÅÇÑ ÀÓ»ó½ÃÇèÀ» À§ÇÑ Çõ½ÅÀûÀÎ ¿¬±¸ µðÀÚÀÎ

Á¦10Àå ÀÓ»ó½ÃÇè ºÐ¼®

Á¦11Àå ÃâÆÇ¹° ºÐ¼®

Á¦12Àå ´ëÇü Á¦¾à ±â¾÷ : º¥Ä¡¸¶Å· ºÐ¼®

Á¦13Àå »ç·Ê ¿¬±¸ : µ¿¹ÝÁø´Ü ¾÷°è ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå ÇâÈÄ ¼ºÀå ±âȸ

Á¦15Àå ¼¼°èÀÇ ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå

Á¦16Àå ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°

Á¦17Àå ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ¾Ï À¯Çüº°

Á¦18Àå ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ÁÖ¿ä Áö¿ªº°

Á¦19Àå °á·Ð

Á¦20Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦21Àå ºÎ·Ï 1 : Ç¥ Çü½Ä µ¥ÀÌÅÍ

Á¦22Àå ºÎ·Ï 2 : ±â¾÷ ¹× ´Üü ¸®½ºÆ®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CANCER BIOMARKERS MARKET: OVERVIEW

As per Roots Analysis, the global cancer biomarkers market is estimated to grow from USD 28.6 billion in the current year to USD 46.7 billion by 2035, at a CAGR of 5% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biomarker

Type of Cancer

Key Geographical Regions

CANCER BIOMARKERS MARKET: GROWTH AND TRENDS

The clinical success of several immunotherapies, such as checkpoint inhibitors, has already been established across multiple solid tumors. However, there still exists an unmet need related to evaluating the type of therapy that is to be used for treating different individuals suffering from a specific type of cancer. This is attributed to the fact that patients suffering from same cancer (same stage of the disease) may have exhibited different molecular profiles and respond differently to recommended drug / therapy types. In order to achieve better results for the patients, it is critical to identify reliable cancer biomarkers. Biomarkers provide valuable information about the molecular characteristics of individual tumors, allowing clinicians to tailor treatment strategies to each patient's unique profile.

The future of cancer biomarkers is promising as they have the potential to be used in various aspects of cancer medicine, such as screening, cancer classification, risk assessment, determination of tumor burden, personalization and monitoring of treatment, and prognosis. Moreover, advancements in genomic, proteomic, metabolomic, and microRNomic profiling, along with other techniques, such as comparative genome hybridization (CGH), single nucleotide polymorphism (SNP) analysis, high throughput screening (HTS) and next-generation sequencing (NGS), are paving the way for the discovery of new tumor signatures. Furthermore, the emergence of powerful proteomic and genomic technologies, combined with the analysis of circulating tumor cells (CTC), cancer stem cell-specific markers and cell-free circulating tumor DNA (ctDNA) are contributing to the development of more sensitive and specific biomarkers for early cancer detection, disease progression monitoring and proper treatment selection. Given the ongoing pace of innovation, and increasing interest towards personalized approaches, the cancer biomarkers market is poised to experience a noteworthy growth in the foreseeable future.

CANCER BIOMARKERS MARKET: KEY INSIGHTS

The report delves into the current state of the cancer biomarkers market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Cancer Biomarkers Market - IMG1
Cancer Biomarkers Market - IMG2

CANCER BIOMARKERS MARKET: KEY SEGMENTS

HER2 Biomarker Occupies the Largest Share of the Cancer Biomarkers Market

Based on the type of biomarker, the market is segmented into HER2, MET, EGFR, PD-L1, NTRK, ALK, novel biomarkers and other biomarkers. At present, HER2 biomarkers hold the maximum share of the cancer biomarkers market. It is worth highlighting that the cancer biomarkers market for EGFR is likely to grow at a relatively higher CAGR in the near future.

Breast Cancer is Likely to Dominate the Cancer Biomarkers Market During the Forecast Period

Based on the type of cancer, the market is segmented into breast cancer, prostate cancer, colorectum cancer, lung cancer, thyroid cancer, bladder cancer, melanoma, non-Hodgkins's lymphoma, endometrial cancer, kidney cancer and leukemia. Currently, breast cancer holds the maximum share of the cancer biomarkers market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cancer Biomarkers Market

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

CANCER BIOMARKERS MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE

7. PRODUCT COMPETITIVENESS ANALYSIS

8. COMPANY PROFILES

9. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS

10. CLINICAL TRIAL ANALYSIS

11. PUBLICATION ANALYSIS

12. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS

13. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY

14. FUTURE GROWTH OPPORTUNITIES

15. GLOBAL CANCER BIOMARKERS MARKET

16. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER

17. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER

18. CANCER BIOMARKERS MARKET, BY KEY GEOGRAPHICAL REGIONS

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â